Apnimed (APMD) stock
New listing, trading since Jul 31, 2026. 61 trading days so far, so 4 of the 14 chart checks wait for more history.
Follow APMD's trial news. Pro members can get an alert when Apnimed files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Key facts on APMD
| Holding it back | Moves 10.4% a day with no profit behind it |
| Latest filing | 10-Q, Sep 8 |
APMD catalysts
After its last report it closed -2.5%.
What's next for APMD, and how long its cash lasts
Next step the company has named
Cash runway
$173M in cash
Dilution on the horizon
No shelf registration or at-the-market program on file in the last three years.
Insiders
Director Paul J. Sekhri bought 12,500 shares on Aug 3.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
- In 15 days
NRXPNRX Pharmaceuticals
- In 27 days
CAPRCapricor Therapeutics
- In 27 days
SVRASavara
Why APMD scores 1
Below AverageTrending down, 3 of 14 chart checks firingWhat the Quality Score means
- +3Chart checks 3 of 14 firing right now, one point each
- −2Volatility moves 10.4% a day with no profit or positive free cash flow over four quarters on file
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
APMD has 3 of 14 chart checks firing
APMD RSI today: 43.3, below its 50-day average
- RSI 1443.3
- MACD (12, 26, 9)Above signal
- 50-day average$23.98
- ADX 1427.5
- Resistance$24.50
- High since listing$35.29
- Low since listing$16.12
- Chart patternNone
- Bollinger Bands (20, 2)Inside
- Volume0.4x
The deep dive on APMD
- What it does and how it makes money
- Where it stands
- Who holds and trades itForm 4, filed Aug 5, 2026
How APMD ranks in Pharma
APMD is #49 of 93 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 49 |
When does APMD report earnings, and what happens after?
Expected to report Wed Nov 11, after the close (in 16 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
What APMD reported on Sep 8, 2026
The quarter
The figures are not read from the release yet.
“The increase was primarily attributable to the factors impacting the Company’s expenses and other income described above.”
Where the sales came from
APMD's results filing gives no sales by line in a table we read.
The outlook
No outlook figures read from this release.
The numbers
- $771M
- today
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Sep 8, 2026 | 0.0% | -2.5% | -11.2% |
Who is trading APMD
APMD insider trades
2 insiders bought $5.2M across 2 filings in the last 6 months. No open-market sales on record. The newest:
APMD's officers and directors
Officers and directors with a Form 4 in the last 12 months.
About Apnimed
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
Listed on Nasdaq on Jul 31, 2026, and is 18% above its $16 offer price now. Its IPO filing and first days
APMD's score card
Pro members see every line of every stock's score.
- What would turn APMD's score around: 3 things
- 2 more filings explained, a plain line each
- Real-time prices, no delay
Straight Answers
Is APMD a good stock to buy? What its Quality Score says
APMD scores 1 today, which Breakaway calls Below Average. It is #49 of 93 in Pharma by Quality Score, with 3 of 14 chart checks firing. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
What is APMD's Quality Score?
APMD scores 1 today, which Breakaway calls Below Average (0 to 5). That is #49 of 93 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind APMD's 1.
Are insiders buying APMD?
2 insiders bought $5.2M across 2 filings in the last 6 months. No open-market sales on record. The newest is Morningside Venture Investments Ltd, 10% owner, who bought $5M on Aug 3. Every filing, with the scored weight, for Pro members.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.